Back
MoonLake Immunotherapeutics Quote, Financials, Valuation and Earnings
Invest. Do Good. Get Rewarded. Just $0.25/Share!
This is a paid advertisement for Mode Mobile Regulation A offering. Please read the offering circular and related risks at invest.modemobile.com.
Buy
62
MLTX
MoonLake Immunotherapeutics
Last Price:
52.02
Seasonality Move:
36.4%
7 Day Trial
ALL ACCESS PASS
$
7
Start Investing Smarter Unlock Louis Navellier's Stock Grader for free
Louis' clients have paid up to $30,000 for these insights - now you can try it at no cost.MoonLake Immunotherapeutics Price Quote
$52.02
+2.20 (+4.42%)
(Updated: November 21, 2024 at 5:55 PM ET)
MoonLake Immunotherapeutics Key Stats
Buy
62
MoonLake Immunotherapeutics (MLTX)
is a Buy
Day range:
$48.91 - $52.09
52-week range:
$37.55 - $64.98
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
0.00
P/B ratio:
6.27%
Volume:
191K
Avg. volume:
228.3K
1-year change:
16.76%
Market cap:
$3.1B
Revenue:
$0
EPS:
$-1.27
How Much Does MoonLake Immunotherapeutics Make?
Data Unavailable
Is MoonLake Immunotherapeutics Growing As A Company?
Data Unavailable
MoonLake Immunotherapeutics Stock Price Performance
-
Did MoonLake Immunotherapeutics Stock Go Up Last Month?
MoonLake Immunotherapeutics share price went up by 1.8% last month -
Did MLTX's Share Price Rise Over The Last Year?
MLTX share price rose by 16.76% over the past 1 year
What Is MoonLake Immunotherapeutics 52-Week High & Low?
-
What Is MoonLake Immunotherapeutics’s 52-Week High Share Price?
MoonLake Immunotherapeutics has traded as high as $64.98 over the past 52 weeks -
What Is MoonLake Immunotherapeutics’s 52-Week Low Share Price?
MoonLake Immunotherapeutics has traded as low as $37.55 over the past 52 weeks
MoonLake Immunotherapeutics Price To Free Cash Flow
Data Unavailable
Is It Risky To Buy MoonLake Immunotherapeutics?
-
How Much Debt Does MoonLake Immunotherapeutics Have?
Total long term debt quarterly is $0 -
How Much Cash Does MoonLake Immunotherapeutics Have?
Cash and short term investments quarterly total is $493.9M -
What Is MoonLake Immunotherapeutics’s Book Value Per Share?
Book value per share is 7.74
Is MoonLake Immunotherapeutics Cash Flow Positive?
-
What Is MLTX Cash Flow From Operations?
Cash flow from operations (TTM) is -$80.5M -
What Is MoonLake Immunotherapeutics’s Cash Flow From Financing?
Cash flow from financing (TTM) is $79.6M -
What Is MoonLake Immunotherapeutics’s Cash Flow From Investing?
Cash flow from investing (TTM) is $58.6M
MoonLake Immunotherapeutics Return On Invested Capital
Data Unavailable
MoonLake Immunotherapeutics Earnings Date & Stock Price
-
What Is MoonLake Immunotherapeutics's Stock Price Today?
A single share of MLTX can be purchased today for 49.82 -
What Is MoonLake Immunotherapeutics’s Stock Symbol?
MoonLake Immunotherapeutics trades on the nasdaq under the ticker symbol: MLTX -
When Is MoonLake Immunotherapeutics’s Next Earnings Date?
The next quarterly earnings date for MoonLake Immunotherapeutics is scheduled on February 28, 2025 -
When Is MLTX's next ex-dividend date?
MoonLake Immunotherapeutics's next ex-dividend date is November 22, 2024 -
How To Buy MoonLake Immunotherapeutics Stock?
You can buy MoonLake Immunotherapeutics shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.
MoonLake Immunotherapeutics Competitors
-
Who Are MoonLake Immunotherapeutics's Competitors?
Below is a list of companies who compete with MoonLake Immunotherapeutics or are related in some way:
MoonLake Immunotherapeutics Dividend Yield
-
What Is MLTX Dividend Yield?
MoonLake Immunotherapeutics’s dividend yield currently is 0% -
What Is MoonLake Immunotherapeutics’s Payout Ratio?
MoonLake Immunotherapeutics’s payout ratio is 0% -
When Did MoonLake Immunotherapeutics Last Pay A Dividend?
The latest dividend pay date is November 22, 2024 -
What Is MoonLake Immunotherapeutics’s Dividend Per Share?
MoonLake Immunotherapeutics pays a dividend of $0.00 per share
MoonLake Immunotherapeutics Analyst Estimates
| YoY Growth | Past Surprise | |
|---|---|---|
| EPS: | 0% | -23.33% |
| Revenue: | 0% | 0% |
Analyst Recommendations
| Buy Recommendations: | 11 |
|---|---|
| Hold Recommendations: | 3 |
| Sell Recommendations: | 0 |
| Price Target: | 73.92 |
| Upside from Last Price: | 48.38% |